Assessment of ADCC activity of therapeutic antibodies: from FcγRIIIa binding kinetics to functional cell-based assays

By
  • Fabian Vandermeers
  • Paula Paci
  • Thomas Henri
  • Arnaud Delobel
Date
Download file

Antibody-dependent cellular cytotoxicity (ADCC) is one of the major mechanisms of action of many therapeutic antibodies. By promoting the interaction between the Fc region of an antibody and Fcγ receptors expressed on immune effector cells, ADCC triggers targeted destruction of antibody-coated cells. Consequently, accurate assessment of ADCC activity is essential during antibody development to ensure product quality, and therapeutic efficacy.

The poster presents a multi-assay workflow including:

  • SPR and BLI for FcγRIIIa binding kinetics and affinity characterisation,
  • Lumit™ assays for rapid evaluation of FcγRIIIa engagement,
  • ADCC reporter assays to assess effector-cell activation and functional potency,
  • Cell killing assays to measure target-cell cytotoxicity and differentiate antibodies with varying potencies.

Together, these orthogonal methods provide a comprehensive understanding of ADCC performance and support antibody characterisation, potency testing, and product development.

Looking for more details?

For a deeper dive into ADCC assessment strategies, assay design, and data interpretation, explore our dedicated Application Note.

Download file

Complete this form and access this document in seconds.

Name
Address
Opt-in